Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis
Objectives: To evaluate the efficacy of 2-valent, 4-valent and 9-valent HPV vaccination in preventing persistent HPV infections and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions among women with different infection statuses at baseline. Methods: PubMed, Web of Science, Cochran...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224004387 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560542945214464 |
|---|---|
| author | Haiyue Wu Lucia Li Kun Fu YuFei Shen Yingnan Lu Zexi Liao Yingzhen Liu Wenting Zha Lisha Wu Yu Zhang |
| author_facet | Haiyue Wu Lucia Li Kun Fu YuFei Shen Yingnan Lu Zexi Liao Yingzhen Liu Wenting Zha Lisha Wu Yu Zhang |
| author_sort | Haiyue Wu |
| collection | DOAJ |
| description | Objectives: To evaluate the efficacy of 2-valent, 4-valent and 9-valent HPV vaccination in preventing persistent HPV infections and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions among women with different infection statuses at baseline. Methods: PubMed, Web of Science, Cochrane, Embase and ClinicalTrials.gov were searched from their inception to March 2024. Randomized controlled trials (RCTs) and post hoc analyses of RCTs reporting the risk of persistent HPV infections and CIN2+ among vaccinated women were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to summarize the intervention effects. Results: Eighteen RCTs and one post hoc analysis of RCTs were included. In the according-to-protocol (ATP) cohorts, the 4-valent vaccine was the most effective against HPV16/18-related persistent infections and CIN2+ (6-month persistent infections (6mPIs): OR 0.05, 95% CI [0.02, 0.15]; 12-month persistent infections (12mPIs): OR 0.02, 95% CI [0.00, 0.18]; CIN2+: OR 0.03 95% CI [0.01, 0.17]). For the total vaccination cohorts (TVCs), the 2-valent vaccine was most effective against HPV16/18-related 12mPIs and CIN2+ (12mPIs: OR 0.15, 95% CI [0.04, 0.63]; CIN2+: OR 0.52 95% CI [0.32, 0.87]), whereas the 4-valent vaccine was most effective against HPV16/18-related 6mPIs (OR 0.08, 95% CI [0.02, 0.28]). Conclusions: Vaccination against HPV can significantly reduce the risk of persistent HPV16/18-related infections and CIN2+, regardless of the HPV infection prevaccination. In addition to 4- and 9-valent vaccines, 2-valent vaccines could also provide satisfactory protection against persistent HPV16/18-related infections and CIN2+, especially over the long term, and may constitute an alternative for government-led vaccination programs in developing countries. |
| format | Article |
| id | doaj-art-28f5791776dd4a1da4655d8f8734a9b1 |
| institution | Kabale University |
| issn | 1201-9712 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-28f5791776dd4a1da4655d8f8734a9b12025-01-04T04:56:04ZengElsevierInternational Journal of Infectious Diseases1201-97122025-02-01151107363Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysisHaiyue Wu0Lucia Li1Kun Fu2YuFei Shen3Yingnan Lu4Zexi Liao5Yingzhen Liu6Wenting Zha7Lisha Wu8Yu Zhang9Department of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaKey Laboratory of Molecular Epidemiology of Hunan Province, School of Medicine, Hunan Normal University, Changsha, ChinaGynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Gynecology, Xiangya Hospital, Central South University, Changsha, China; Gynecological Oncology Research and Engineering Center of Hunan Province, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; Corresponding author Yu ZhangObjectives: To evaluate the efficacy of 2-valent, 4-valent and 9-valent HPV vaccination in preventing persistent HPV infections and cervical intraepithelial neoplasia grade 2 or higher (CIN2+) lesions among women with different infection statuses at baseline. Methods: PubMed, Web of Science, Cochrane, Embase and ClinicalTrials.gov were searched from their inception to March 2024. Randomized controlled trials (RCTs) and post hoc analyses of RCTs reporting the risk of persistent HPV infections and CIN2+ among vaccinated women were included. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to summarize the intervention effects. Results: Eighteen RCTs and one post hoc analysis of RCTs were included. In the according-to-protocol (ATP) cohorts, the 4-valent vaccine was the most effective against HPV16/18-related persistent infections and CIN2+ (6-month persistent infections (6mPIs): OR 0.05, 95% CI [0.02, 0.15]; 12-month persistent infections (12mPIs): OR 0.02, 95% CI [0.00, 0.18]; CIN2+: OR 0.03 95% CI [0.01, 0.17]). For the total vaccination cohorts (TVCs), the 2-valent vaccine was most effective against HPV16/18-related 12mPIs and CIN2+ (12mPIs: OR 0.15, 95% CI [0.04, 0.63]; CIN2+: OR 0.52 95% CI [0.32, 0.87]), whereas the 4-valent vaccine was most effective against HPV16/18-related 6mPIs (OR 0.08, 95% CI [0.02, 0.28]). Conclusions: Vaccination against HPV can significantly reduce the risk of persistent HPV16/18-related infections and CIN2+, regardless of the HPV infection prevaccination. In addition to 4- and 9-valent vaccines, 2-valent vaccines could also provide satisfactory protection against persistent HPV16/18-related infections and CIN2+, especially over the long term, and may constitute an alternative for government-led vaccination programs in developing countries.http://www.sciencedirect.com/science/article/pii/S1201971224004387Human papillomavirusVaccinesPersistent infectionsCervical intraepithelial neoplasiaNetwork meta-analysis |
| spellingShingle | Haiyue Wu Lucia Li Kun Fu YuFei Shen Yingnan Lu Zexi Liao Yingzhen Liu Wenting Zha Lisha Wu Yu Zhang Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis International Journal of Infectious Diseases Human papillomavirus Vaccines Persistent infections Cervical intraepithelial neoplasia Network meta-analysis |
| title | Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis |
| title_full | Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis |
| title_fullStr | Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis |
| title_full_unstemmed | Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis |
| title_short | Effects of different-valent vaccines against human papillomavirus (HPV) to prevent persistent HPV16/18 infections and CIN2+ in women: a systematic review and network meta-analysis |
| title_sort | effects of different valent vaccines against human papillomavirus hpv to prevent persistent hpv16 18 infections and cin2 in women a systematic review and network meta analysis |
| topic | Human papillomavirus Vaccines Persistent infections Cervical intraepithelial neoplasia Network meta-analysis |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224004387 |
| work_keys_str_mv | AT haiyuewu effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT luciali effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT kunfu effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT yufeishen effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT yingnanlu effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT zexiliao effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT yingzhenliu effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT wentingzha effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT lishawu effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis AT yuzhang effectsofdifferentvalentvaccinesagainsthumanpapillomavirushpvtopreventpersistenthpv1618infectionsandcin2inwomenasystematicreviewandnetworkmetaanalysis |